Autoimmune hepatitis (AIH) presents ongoing challenges in diagnosis and treatment, requiring continuous research to improve patient outcomes. Professor Michael A. Heneghan has been a leading voice in AIH research, providing critical insights into its pathogenesis, clinical management, and emerging therapies. In a recent Journal of Hepatology publication, he examines key advancements in the field, offering a forward-looking perspective on improving care for AIH patients.
His work highlights AIH as a primarily T cell-driven disease, while also recognizing the role of B cells in autoantibody production and liver infiltration. He emphasizes the importance of liver biopsy in diagnosis, with newly refined histological criteria enhancing accuracy. With AIH incidence rising, particularly among older populations, his research explores how biological therapies are transforming treatment approaches.
This comprehensive review, with contributions from Professor Ansgar Wilhelm Lohse, offers an essential update on the evolving landscape of AIH management. Professor Heneghan’s continued leadership in hepatology is shaping the future of AIH care, driving innovation in both research and clinical practice.
Looking forward to more work from Professor Michael A. Heneghan in advancing the understanding and treatment of AIH!
For more details: https://lnkd.in/e3KiBYRQ
